Search Results for "Cvs Minute Clinic Shingles Vaccine"

13:50 EST 4th March 2015 | BioPortfolio

Matching Channels

Varicella

Varicella zoster virus (VZV) is one of eight herpes viruses known to infect humans (and other vertebrates). Varicella-zoster virus is known by many names, including: chickenpox virus, varicella viru...

HPV vaccine

Smallpox Vaccine MVA

Haemophilus b Vaccine GSK

Rotavirus Vaccine GSK

Matching News

GSK shingles vaccine on form

GlaxoSmithKline will be celebrating following the successful Phase III study of its shingles vaccine HZ/su that has met its primary endpoint. HZ/su reduced the risk of shingles by 97.2% in adults aged...

New GSK shingles vaccine may challenge Merck after strong test data

LONDON (Reuters) - An experimental shingles vaccine from GlaxoSmithKline has produced impressive results in a late-stage study, giving the group's expanding vaccine unit a potential $1 billion boost. ...

GSK Shingles Vaccine Hits Goal in Major Study

GSK announced that a pivotal phase 3 study to assess the efficacy of HZ/su, an investigational vaccine for the prevention of shingles, has met its primary endpoint. Analysis of the primary endpoint s...

GlaxoSmithKline shingles vaccine hits goal in major study

LONDON, Dec 18 (Reuters) - An experimental vaccine against shingles from GlaxoSmithKline met its goal in a late-stage study, in a boost for the company's vaccine unit, which is expanding part of its o...

BRIEF-GSK says shingles vaccine meets primary endpoint in late-stage trial

* Pivotal phase III study to assess efficacy of HZ/su, an investigational vaccine for prevention of shingles, has met its primary endpoint

GSK, Agenus shingles vaccine meets primary endpoint

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) said its HZ/su herpes zoster vaccine (GSK1437173A) met the primary endpoint of reducing the risk of shingles by 97.2% in people aged 50 and older vs. placebo in...

GSK shingles vaccine candidate meets Ph III primary endpoint

UK pharma major GlaxoSmithKline today released pivotal Phase III study data to assess the efficacy of HZ/su, an investigational vaccine for the prevention of shingles (post-herpetic neuralgia, or herp...

GSK's Phase III trial of shingles vaccine candidate meets primary endpoint

GlaxoSmithKline (GSK) has reported that its Phase III trial designed to evaluate the efficacy of HZ/su, an investigational vaccine for the prevention of shingles, met its primary endpoint.

Matching PubMed Articles

Shingles vaccination: background and advice for community nurses.

Shingles (or zoster) is a reactivation of an existing varicella-zoster virus (VZV) infection. During the initial infection, VZV causes a systemic disease known as varicella or chickenpox, and this ini...

Impact of pharmacist integration in a pediatric primary care clinic on vaccination errors: A retrospective review.

OBJECTIVE To measure the impact of ambulatory clinical pharmacist integration in a pediatric primary care clinic on vaccination error rates and to evaluate missed opportunities. METHODS A retrospecti...

The immunogenicity and safety of zoster vaccine in Taiwanese adults.

The efficacy and safety of ZOSTAVAX™ in subjects 60 years of age and older was established in the Shingles Prevention Study (SPS) and in subjects 50 to 59 years of age in the ZOSTAVAX™ Efficacy an...

Parent perceptions important for HPV vaccine initiation among low income adolescent girls.

The study aims were to assess the influence of provider recommendations on parental vaccine perceptions and identify the most potent parent vaccine perceptions for HPV vaccine series initiation consid...

The development of a recombinant hepatitis E vaccine HEV 239.

Hepatitis E virus (HEV) infection is one of the main causes of acute hepatitis worldwide. A recombinant hepatitis E vaccine, HEV 239, has been licensed in China for immunizing adults of 16 year old an...

Search Whole site using Google

Loading
Search BioPortfolio:
Loading
Advertisement
Advertisement
Advertisement Advertisement